Loading...

ACADIA Pharmaceuticals

Nasdaq:ACAD
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ACAD
Nasdaq
$4B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The last earnings update was 47 days ago. More info.


Add to Portfolio Compare Print
ACAD Share Price and Events
7 Day Returns
1.2%
NasdaqGS:ACAD
2.8%
US Biotechs
0.1%
US Market
1 Year Returns
58.8%
NasdaqGS:ACAD
-5.6%
US Biotechs
1.2%
US Market
ACAD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ACADIA Pharmaceuticals (ACAD) 1.2% 3.6% -1.1% 58.8% -25.9% 13.6%
US Biotechs 2.8% 1.7% -6% -5.6% 14.4% 9.6%
US Market 0.1% 0.6% 0.9% 1.2% 36.7% 37.9%
1 Year Return vs Industry and Market
  • ACAD outperformed the Biotechs industry which returned -5.6% over the past year.
  • ACAD outperformed the Market in United States of America which returned 1.2% over the past year.
Price Volatility
ACAD
Industry
5yr Volatility vs Market
Related Companies

Value

 Is ACADIA Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of ACADIA Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for ACADIA Pharmaceuticals.

NasdaqGS:ACAD Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 12 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:ACAD
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.32
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.323 (1 + (1- 21%) (0.3%))
1.218
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.22
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.218 * 5.96%)
9.99%

Discounted Cash Flow Calculation for NasdaqGS:ACAD using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for ACADIA Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:ACAD DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 9.99%)
2019 -191.45 Analyst x2 -174.06
2020 -98.45 Analyst x4 -81.38
2021 169.63 Analyst x3 127.48
2022 364.77 Analyst x3 249.22
2023 479.70 Analyst x2 297.97
2024 575.09 Est @ 19.89% 324.78
2025 659.86 Est @ 14.74% 338.80
2026 733.34 Est @ 11.14% 342.33
2027 796.51 Est @ 8.61% 338.04
2028 851.07 Est @ 6.85% 328.38
Present value of next 10 years cash flows $2,091.56
NasdaqGS:ACAD DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $851.07 × (1 + 2.73%) ÷ (9.99% – 2.73%)
$12,040.58
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $12,040.58 ÷ (1 + 9.99%)10
$4,645.84
NasdaqGS:ACAD Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $2,091.56 + $4,645.84
$6,737.40
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $6,737.40 / 144.17
$46.73
NasdaqGS:ACAD Discount to Share Price
Calculation Result
Value per share (USD) From above. $46.73
Current discount Discount to share price of $25.93
= -1 x ($25.93 - $46.73) / $46.73
44.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price ACADIA Pharmaceuticals is available for.
Intrinsic value
45%
Share price is $25.93 vs Future cash flow value of $46.73
Current Discount Checks
For ACADIA Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • ACADIA Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • ACADIA Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ACADIA Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ACADIA Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:ACAD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-2.10
NasdaqGS:ACAD Share Price ** NasdaqGS (2019-06-18) in USD $25.93
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.39x
United States of America Market PE Ratio Median Figure of 3,092 Publicly-Listed Companies 17.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ACADIA Pharmaceuticals.

NasdaqGS:ACAD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ACAD Share Price ÷ EPS (both in USD)

= 25.93 ÷ -2.10

-12.34x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ACADIA Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.
  • ACADIA Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does ACADIA Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGS:ACAD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -12.34x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts
65.7%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 1.11x
United States of America Market PEG Ratio Median Figure of 2,126 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ACADIA Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ACADIA Pharmaceuticals's assets?
Raw Data
NasdaqGS:ACAD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $2.90
NasdaqGS:ACAD Share Price * NasdaqGS (2019-06-18) in USD $25.93
United States of America Biotechs Industry PB Ratio Median Figure of 425 Publicly-Listed Biotechs Companies 3.03x
United States of America Market PB Ratio Median Figure of 5,244 Publicly-Listed Companies 1.79x
NasdaqGS:ACAD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ACAD Share Price ÷ Book Value per Share (both in USD)

= 25.93 ÷ 2.90

8.93x

* Primary Listing of ACADIA Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ACADIA Pharmaceuticals is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess ACADIA Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. ACADIA Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is ACADIA Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 12 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
65.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ACADIA Pharmaceuticals expected to grow at an attractive rate?
  • ACADIA Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • ACADIA Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • ACADIA Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:ACAD Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:ACAD Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts 65.7%
NasdaqGS:ACAD Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 12 Analysts 35.4%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.9%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18.3%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:ACAD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:ACAD Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,264 572 530 2
2022-12-31 935 342 473 4
2021-12-31 789 96 263 7
2020-12-31 420 -116 -179 12
2019-12-31 293 -186 -275 12
NasdaqGS:ACAD Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 238 -186 -276
2018-12-31 224 -167 -245
2018-09-30 208 -158 -249
2018-06-30 185 -175 -252
2018-03-31 158 -192 -256
2017-12-31 125 -218 -289
2017-09-30 93 -251 -299
2017-06-30 63 -242 -306
2017-03-31 33 -240 -309
2016-12-31 17 -208 -271
2016-09-30 5 -182 -238
2016-06-30 0 -165 -206

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ACADIA Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • ACADIA Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:ACAD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below

All data from ACADIA Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:ACAD Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 3.26 3.42 3.10 2.00
2022-12-31 2.12 3.50 1.00 3.00
2021-12-31 1.38 2.56 -0.13 5.00
2020-12-31 -1.25 -0.24 -1.92 10.00
2019-12-31 -1.91 -1.83 -1.96 11.00
NasdaqGS:ACAD Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -2.10
2018-12-31 -1.94
2018-09-30 -1.99
2018-06-30 -2.03
2018-03-31 -2.07
2017-12-31 -2.36
2017-09-30 -2.46
2017-06-30 -2.53
2017-03-31 -2.61
2016-12-31 -2.34
2016-09-30 -2.15
2016-06-30 -1.93

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • ACADIA Pharmaceuticals is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess ACADIA Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ACADIA Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has ACADIA Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ACADIA Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ACADIA Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare ACADIA Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ACADIA Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
ACADIA Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ACADIA Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:ACAD Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 237.90 -276.20 297.92
2018-12-31 223.81 -245.19 265.76
2018-09-30 207.80 -248.57 258.18
2018-06-30 185.07 -251.68 258.68
2018-03-31 158.48 -255.86 250.33
2017-12-31 124.90 -289.40 255.06
2017-09-30 93.30 -299.23 246.04
2017-06-30 62.99 -305.59 234.98
2017-03-31 32.61 -309.47 224.63
2016-12-31 17.33 -271.39 186.46
2016-09-30 5.39 -238.48 151.41
2016-06-30 0.16 -205.77 121.18
2016-03-31 0.06 -173.83 91.53
2015-12-31 0.06 -164.44 78.70
2015-09-30 0.09 -147.03 66.51
2015-06-30 0.07 -132.91 54.26
2015-03-31 0.09 -115.02 41.09
2014-12-31 0.12 -92.48 32.75
2014-09-30 0.11 -76.16 26.60
2014-06-30 0.34 -62.07 22.35
2014-03-31 0.76 -49.65 16.89
2013-12-31 1.15 -37.95 12.72
2013-09-30 1.49 -32.71 10.74
2013-06-30 4.73 -24.42 8.43
2013-03-31 4.87 -20.75 7.49
2012-12-31 4.91 -20.85 7.00
2012-09-30 5.12 -19.34 6.18
2012-06-30 2.22 -22.01 6.21

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ACADIA Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ACADIA Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ACADIA Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ACADIA Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ACADIA Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is ACADIA Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ACADIA Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ACADIA Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ACADIA Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ACADIA Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • ACADIA Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ACADIA Pharmaceuticals Company Filings, last reported 2 months ago.

NasdaqGS:ACAD Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 418.36 11.22 414.32
2018-12-31 479.08 0.00 473.52
2018-09-30 223.44 0.00 214.14
2018-06-30 264.72 0.00 256.86
2018-03-31 304.17 0.00 298.06
2017-12-31 335.29 0.00 341.34
2017-09-30 377.33 0.00 366.63
2017-06-30 415.14 0.00 417.32
2017-03-31 457.52 0.00 469.48
2016-12-31 518.41 0.00 529.04
2016-09-30 578.06 0.00 588.86
2016-06-30 408.82 0.00 412.56
2016-03-31 445.25 0.00 457.24
2015-12-31 199.76 0.00 215.13
2015-09-30 227.35 0.00 240.69
2015-06-30 255.82 0.00 270.78
2015-03-31 285.09 0.00 297.89
2014-12-31 309.49 0.00 322.49
2014-09-30 330.49 0.00 337.80
2014-06-30 350.11 0.00 354.45
2014-03-31 365.46 0.00 369.29
2013-12-31 182.13 0.00 185.79
2013-09-30 180.75 0.00 196.18
2013-06-30 181.48 0.00 205.45
2013-03-31 79.66 0.00 101.46
2012-12-31 84.98 0.00 107.97
2012-09-30 17.66 0.00 23.06
2012-06-30 12.71 0.01 21.35
  • ACADIA Pharmaceuticals has no debt.
  • ACADIA Pharmaceuticals had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ACADIA Pharmaceuticals has sufficient cash runway for 2.2 years based on current free cash flow.
  • ACADIA Pharmaceuticals has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of -1.3% each year.
X
Financial health checks
We assess ACADIA Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ACADIA Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is ACADIA Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ACADIA Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought $2,000 of ACADIA Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ACADIA Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ACADIA Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:ACAD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:ACAD Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ACADIA Pharmaceuticals has not reported any payouts.
  • Unable to verify if ACADIA Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ACADIA Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ACADIA Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of ACADIA Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess ACADIA Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ACADIA Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ACADIA Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of ACADIA Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Steve Davis
COMPENSATION $6,508,032
AGE 57
TENURE AS CEO 3.8 years
CEO Bio

Mr. Stephen R. Davis, also known as Steve, J.D., has been the Chief Executive Officer of ACADIA Pharmaceuticals, Inc. since September 1, 2015 and served as its Chief Financial Officer from July 15, 2014 to September 6, 2015. Mr. Davis served as President of ACADIA Pharmaceuticals, Inc. since September 1, 2015 until November 19, 2018. He served as the Chief Business Officer and Executive Vice President of ACADIA Pharmaceuticals, Inc. from July 15, 2014 to September 1, 2015 and as its Interim Chief Executive Officer from March 2015 to August 2015. Mr. Davis served as the Chief Operating Officer and Executive Vice President of Heron Therapeutics, Inc. from May 2, 2013 to July 2, 2014. Mr. Davis has over 20 years of executive-level experience in the pharmaceutical industry. He served as Chief Financial Officer and Chief Accounting Officer of Heron Therapeutics, Inc. since October 29, 2013. He served as the Chief Operating Officer and Executive Vice President at Ardea Biosciences, Inc. from April 6, 2010 to 2013. He served at Neurogen Corporation as Chief Executive Officer since February 2008, President since September 2007, Chief Operating Officer since April 2005, Principal Financial Officer from 1994 to April 2008, Chief Business Officer from January 2001 to April 2008, Executive Vice President since September 2001, Secretary until February 21, 2007 and Director since September 2001. He joined Neurogen Corp., in 1994 as Vice President of Finance and was responsible for its business operations including the business development, finance and legal functions. From 1990 to June 1994, he was corporate and securities attorney at Milbank, Tweed, Hadley & McCloy LLP. He practiced as a Certified Public Accountant with Arthur Andersen & Co. and as a corporate and securities attorney with a Wall Street law firm. He has been a Director at Bellicum Pharmaceuticals, Inc. since July 2015. He has been a Director of Furiex Pharmaceuticals, Inc since May 24, 2013 and ACADIA Pharmaceuticals, Inc. since September 2015. He served as a Director of Synageva BioPharma Corp. from November 2011 to June 22, 2015. He served as a Director of Trimeris Inc. since June 2007. He served as a Director of Heron Therapeutics, Inc. from February 2010 to February 23, 2011 and again since June 2012. He served as a Director of Neurogen from September 2001 to December 2009. Mr. Davis received his BS in Accounting from Southern Nazarene University and a JD degree from Vanderbilt University.

CEO Compensation
  • Steve's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Steve's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the ACADIA Pharmaceuticals management team in years:

0.8
Average Tenure
56
Average Age
  • The average tenure for the ACADIA Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Steve Davis

TITLE
CEO & Director
COMPENSATION
$7M
AGE
57
TENURE
3.8 yrs

Serge Stankovic

TITLE
President
COMPENSATION
$6M
AGE
61
TENURE
0.6 yrs

Austin Kim

TITLE
Executive VP
COMPENSATION
$2M
AGE
54
TENURE
0.9 yrs

Michael Yang

TITLE
Executive VP & Chief Commercial Officer
COMPENSATION
$3M
AGE
56
TENURE
2.3 yrs

Elena Ridloff

TITLE
Executive VP & CFO
AGE
38
TENURE
0.7 yrs

Eric Miller

TITLE
Controller & Principal Accounting Officer
AGE
39
TENURE
0.6 yrs

Bob Mischler

TITLE
Senior Vice President of Strategy & Technology Operations

Eliseo Salinas

TITLE
Senior VP
AGE
62
TENURE
0.8 yrs

Mark Johnson

TITLE
Vice President of Investor Relations

Ryan Brown

TITLE
Chief Compliance Officer & VP
TENURE
3.8 yrs
Board of Directors Tenure

Average tenure and age of the ACADIA Pharmaceuticals board of directors in years:

3.7
Average Tenure
61
Average Age
  • The tenure for the ACADIA Pharmaceuticals board of directors is about average.
Board of Directors

Stephen Biggar

TITLE
Chairman of the Board
COMPENSATION
$276K
AGE
47
TENURE
3 yrs

Steve Davis

TITLE
CEO & Director
COMPENSATION
$7M
AGE
57
TENURE
3.8 yrs

Laura Brege

TITLE
Independent Director
COMPENSATION
$794K
AGE
60
TENURE
11.1 yrs

Dan Soland

TITLE
Independent Director
COMPENSATION
$413K
AGE
62
TENURE
4.3 yrs

Carol Tamminga

TITLE
Member of the Scientific and Clinical Advisory Board

Herb Meltzer

TITLE
Member of the Scientific and Clinical Advisory Board

Arvid Carlsson

TITLE
Member of the Scientific and Clinical Advisory Board
AGE
95

Paul Anderson

TITLE
Member of the Scientific and Clinical Advisory Board
AGE
79

Ed Harrigan

TITLE
Director
COMPENSATION
$395K
AGE
65
TENURE
3.6 yrs

Jim Baker

TITLE
Independent Director
COMPENSATION
$231K
AGE
51
TENURE
3.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
04. Dec 18 Buy Baker Bros. Advisors LP Company 30. Nov 18 30. Nov 18 11,764,705 $17.00 $199,999,985
24. Sep 18 Buy Baker Bros. Advisors LP Company 20. Sep 18 20. Sep 18 1,210,776 $19.09 $22,646,989
X
Management checks
We assess ACADIA Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ACADIA Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Profit Outlook

I’ve put together a brief outline of industry analyst expectations for ACAD, its year of breakeven and its implied growth rate. … View our latest analysis for ACADIA Pharmaceuticals Consensus from the 12 Biotechs analysts is ACAD is on the verge of breakeven. … ACAD currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.

Simply Wall St -

Are Investors Undervaluing ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) By 44%?

A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we discount the value of these future cash flows to their estimated value in today's dollars: 10-year free cash flow (FCF) forecast 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Levered FCF ($, Millions) $-191.45 $-98.45 $169.63 $364.77 $479.70 $575.09 $659.86 $733.34 $796.51 $851.07 Growth Rate Estimate Source Analyst x2 Analyst x4 Analyst x3 Analyst x3 Analyst x2 Est @ 19.89% Est @ 14.74% Est @ 11.14% Est @ 8.61% Est @ 6.85% Present Value ($, Millions) Discounted @ 10.22% $-173.70 $-81.04 $126.70 $247.18 $294.93 $320.81 $333.97 $336.76 $331.86 $321.72 Present Value of 10-year Cash Flow (PVCF)= $2.06b "Est" = FCF growth rate estimated by Simply Wall St We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. … The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 10-year government bond rate of 2.7%. … Terminal Value (TV) = FCF2029 × (1 + g) ÷ (r – g) = US$851m × (1 + 2.7%) ÷ (10.2% – 2.7%) = US$12b Present Value of Terminal Value (PVTV) = TV / (1 + r)10 = $US$12b ÷ ( 1 + 10.2%)10 = $4.41b The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is $6.47b.

Simply Wall St -

Is ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) A Financially Strong Company?

Mid-caps stocks, like ACADIA Pharmaceuticals Inc. … Note that this commentary is very high-level and solely focused on financial health, so I suggest you dig deeper yourself. … See our latest analysis for ACADIA Pharmaceuticals

Simply Wall St -

If You Had Bought ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Five Years Ago, You Could Pocket A 30% Gain Today

Because ACADIA Pharmaceuticals is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth. … In the last 5 years ACADIA Pharmaceuticals saw its revenue grow at 81% per year.

Simply Wall St -

Is ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Potentially Underrated?

(NASDAQ:ACAD) is a stock with outstanding fundamental characteristics. … When we build an investment case, we need to look at the stock with a holistic perspective. … In the case of ACAD, it

Simply Wall St -

ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Profit Outlook

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. … The US$3.3b market-cap company’s loss lessens since it announced a -US$289.4m bottom-line in the full financial year, compared to the latest trailing-twelve-month loss of -US$248.6m, as it approaches breakeven. … Check out our latest analysis for ACADIA Pharmaceuticals

Simply Wall St -

Have Insiders Been Buying ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares This Year?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … The Last 12 Months Of Insider Transactions At ACADIA Pharmaceuticals. … In the last twelve months, the biggest single purchase by an insider was when Independent Director Daniel Soland bought US$235k worth of shares at a price of US$24.52 per share.

Simply Wall St -

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Is Trading At A 48.53% Discount

Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of ACADIA Pharmaceuticals Inc. … by taking the expected future cash flows and discounting them to their present value. … If you are reading this and its not January 2019 then I highly recommend you check out the latest calculation for ACADIA Pharmaceuticals by following the link below

Simply Wall St -

Is ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Liquidity Good Enough?

Stocks with market capitalization between $2B and $10B, such as ACADIA Pharmaceuticals Inc. … Let’s take a look at ACAD’s debt concentration and assess their financial liquidity to get an idea of their ability to fund strategic acquisitions and grow through cyclical pressures. … Check out our latest analysis for ACADIA Pharmaceuticals

Simply Wall St -

Could The ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) Ownership Structure Tell Us Something Useful?

Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … It has a market capitalization of US$2.7b, which means it would generally expect to see some institutions on the share registry. … institutions are noticeable on the share registry.

Simply Wall St -

Company Info

Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Details
Name: ACADIA Pharmaceuticals Inc.
ACAD
Exchange: NasdaqGS
Founded: 1993
$3,738,222,383
144,165,923
Website: http://www.acadia-pharm.com
Address: ACADIA Pharmaceuticals Inc.
3611 Valley Centre Drive,
Suite 300,
San Diego,
California, 92130,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ACAD Common Stock Nasdaq Global Select US USD 27. May 2004
DB DR6 Common Stock Deutsche Boerse AG DE EUR 27. May 2004
Number of employees
Current staff
Staff numbers
465
ACADIA Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/18 23:53
End of day share price update: 2019/06/18 00:00
Last estimates confirmation: 2019/06/11
Last earnings filing: 2019/05/02
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.